J. Virkus

Iron Chelation with Deferasirox (Exjade®) Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS)

D. Steensma, A. Raza, M. Baer, 2008 .

Deferasirox (ICL670; Exjade®) Reduces Serum Ferritin (SF) and Labile Plasma Iron (LPI) in Patients with Myelodysplastic Syndromes (MDS).

D. Steensma, A. Raza, M. Baer, 2007 .

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

E. Estey, D. Gilliland, D. Gilliland, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Deferasirox (Exjade®) Monotherapy Significantly Reduces Cardiac Iron Burden in Chronically Transfused β-Thalassemia Patients: An MRI T2* Study

T. Coates, A. Thompson, J. Wood, 2008 .

Exjade® Reduces Cardiac Iron Burden in Chronically Transfused β-Thalassemia Patients: An MRI T2* Study.

T. Coates, A. Thompson, J. Wood, 2007 .

CALGB 10603 (RATIFY): A randomized phase III study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naive patients with FLT3 mutated AML.

R. Larson, R. Stone, G. Ehninger, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.